Johnson & Johnson Presents New Data at IMS 2026 Highlighting Its Industry-leading Multiple Myeloma Portfolio, With the Goal of Advancing the Potential for Cure
September 10, 2026
September 10, 2026
RARITAN, New Jersey, Sept. 10 -- Johnson and Johnson Innovative Medicine issued the following news release on Sept. 9, 2026:
* * *
Johnson & Johnson presents new data at IMS 2026 highlighting its industry-leading multiple myeloma portfolio, with the goal of advancing the potential for cure
* 35+ abstracts demonstrate new findings across DARZALEX(R), TECVAYLI(R) plus DARZALEX FASPRO(R), CARVYKTI(R), TALVEY(R), and the investigational trispecific antibody . . .
* * *
Johnson & Johnson presents new data at IMS 2026 highlighting its industry-leading multiple myeloma portfolio, with the goal of advancing the potential for cure
* 35+ abstracts demonstrate new findings across DARZALEX(R), TECVAYLI(R) plus DARZALEX FASPRO(R), CARVYKTI(R), TALVEY(R), and the investigational trispecific antibody . . .